
Glyn B Steventon

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7833698/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Phenylalanine monooxygenase and the â€~sulfoxidation polymorphism'; the salient points. Drug Metabolism and Personalized Therapy, 2022, .	0.6	О
2	S-Carboxymethyl-l-cysteine: a multiple dosing study using pharmacokinetic modelling. Xenobiotica, 2021, 51, 865-870.	1.1	1
3	Uridine diphosphate glucuronosyltransferase 1A1. Xenobiotica, 2020, 50, 64-76.	1.1	21
4	PREFACE for the special issue of xenobiotica on "pharmacogenetics of drug metabolism― Xenobiotica, 2020, 50, 1-2.	1.1	3
5	Phenylalanine 4-monooxygenase: the "sulfoxidation polymorphism― Xenobiotica, 2020, 50, 51-63.	1.1	5
6	Drug S-oxidation and phenylalanine hydroxylase: a biomarker for neurodegenerative susceptibility in Parkinson's disease and amyotrophic lateral sclerosis. Drug Metabolism and Personalized Therapy, 2019, 34, .	0.6	2
7	The S-oxidation of S-carboxymethyl-L-cysteine in hepatic cytosolic fractions from BTBR and phenylketonuria enu1 and enu2 mice. Xenobiotica, 2019, 49, 495-502.	1.1	2
8	Phenylalanine hydroxylase: A biomarker of disease susceptibility in Parkinson's disease and Amyotrophic lateral sclerosis. Medical Hypotheses, 2018, 118, 29-33.	1.5	4
9	Comparison of the sulfur-oxygenation of cysteine and S-carboxymethyl-‹scp>l‹/scp>-cysteine in human hepatic cytosol and the rÃ1e of cysteine dioxygenase. Journal of Pharmacy and Pharmacology, 2018, 70, 1069-1077.	2.4	5
10	Xenobiotic Conjugation with Dicarboxylic Acids. Current Drug Metabolism, 2018, 19, 1130-1137.	1.2	0
11	Phenylalanine monooxygenase and the sulfur oxygenation of S-carboxymethyl-l-cysteine in mice. Xenobiotica, 2016, 46, 379-384.	1.1	5
12	S-carboxymethyl-l-cysteine and it (R/S)-S-oxides in beagle dog plasma and hepatic cytosol. Xenobiotica, 2015, 45, 1047-1053.	1.1	2
13	Drug peptide conjugates in human urine?. Xenobiotica, 2014, 44, 89-93.	1.1	Ο
14	S-Carboxymethyl-L-cysteine. Drug Metabolism Reviews, 2012, 44, 129-147.	3.6	17
15	An investigation into possible xenobiotic–endobiotic inter-relationships involving the amino acid analogue drug, S-carboxymethyl-l-cysteine and plasma amino acids in humans. Amino Acids, 2012, 42, 1967-1973.	2.7	5
16	Recombinant heteromeric phenylalanine monooxygenase and the oxygenation of carbon and sulfur substrates. Journal of Pharmacy and Pharmacology, 2011, 63, 558-564.	2.4	5
17	Characterization and purification of the vitamin K1 2,3 epoxide reductase system from rat liver. Journal of Pharmacy and Pharmacology, 2010, 53, 481-486.	2.4	20
18	Lack of congruence between cysteine dioxygenase activity and S-carboxymethyl-l-cysteine S-oxidation activity in rat cytosol. Journal of Pharmacy and Pharmacology, 2010, 56, 993-1000.	2.4	6

GLYN B STEVENTON

#	Article	IF	CITATIONS
19	In-vitro effect of flavonoids from Solidago canadensis extract on glutathione S-transferase. Journal of Pharmacy and Pharmacology, 2010, 58, 251-256.	2.4	23
20	Human phenylalanine monooxygenase and thioether metabolism. Journal of Pharmacy and Pharmacology, 2010, 61, 63-67.	2.4	14
21	The pharmacokinetics of orally administered S-carboxymethyl-l-cysteine in the dog, calf and sheep. European Journal of Pharmaceutical Sciences, 2010, 39, 219-223.	4.0	5
22	Use of Human Microsomes and Deuterated Substrates: An Alternative Approach for the Identification of Novel Metabolites of Ketamine by Mass Spectrometry. Drug Metabolism and Disposition, 2009, 37, 1769-1778.	3.3	54
23	Metabolic Fate of Phenothiazine in the Marmoset (Callithrix jacchus). Drug Metabolism and Drug Interactions, 2009, 24, 137-152.	0.3	1
24	Mouse recombinant phenylalanine monooxygenase and the <i>S</i> â€oxygenation of thioether substrates. Journal of Biochemical and Molecular Toxicology, 2009, 23, 119-124.	3.0	9
25	The activity of wild type and mutant phenylalanine hydroxylase with respect to the C-oxidation of phenylalanine and the S-oxidation of S-carboxymethyl-l-cysteine. Molecular Genetics and Metabolism, 2009, 96, 27-31.	1.1	17
26	Measurement of Phenylalanine Monooxygenase (PAH) Activities. Current Protocols in Toxicology / Editorial Board, Mahin D Maines (editor-in-chief) [et Al], 2009, 41, Unit4.29.	1.1	1
27	Phenylalanine 4-monooxygenase and the role of endobiotic metabolism enzymes in xenobiotic biotransformation. Expert Opinion on Drug Metabolism and Toxicology, 2009, 5, 1213-1221.	3.3	7
28	Phenylalanine 4-monooxygenase and the S-Oxidation of S-Carboxymethyl-L-cysteine by Human Cytosolic Fractions. Drug Metabolism and Drug Interactions, 2008, 23, 261-82.	0.3	10
29	The sulphorhodamine (SRB) assay and other approaches to testing plant extracts and derived compounds for activities related to reputed anticancer activity. Methods, 2007, 42, 377-387.	3.8	250
30	CARBOCYSTEINE THERAPY IN OLDER PEOPLE WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE. Journal of the American Geriatrics Society, 2006, 54, 1792-1793.	2.6	4
31	PHENYLALANINE 4-MONOOXYGENASE AND THE S-OXIDATION OF S-CARBOXYMETHYL-L-CYSTEINE IN HepG2 CELLS. Drug Metabolism and Drug Interactions, 2005, 21, 1-18.	0.3	15
32	Phenylalanine 4-Monooxygenase and the S-Oxidation of S-Carboxymethyl-L-cysteine. Drug Metabolism and Drug Interactions, 2004, 20, 159-174.	0.3	16
33	CYP1A2 IN A SMOKING AND A NON-SMOKING POPULATION: CORRELATION OF URINARY AND SALIVARY PHENOTYPIC RATIOS. Drug Metabolism and Drug Interactions, 2004, 20, 247-61.	0.3	10
34	Phenylalanine hydroxylase: possible involvement in the S-oxidation of S-carboxymethyl-l-cysteine. Analytical Biochemistry, 2004, 335, 91-97.	2.4	18
35	An Investigation into the Inter-Relationships of Sulphur Xeno- Biotransformation Pathways in Parkinson's and Motor Neurone Diseases. Drug Metabolism and Drug Interactions, 2003, 19, 223-240.	0.3	5
36	Catalytic properties of CYP1A isoforms in the liver of an agnathan (Lampetra fluviatilis) and two species of teleost (Pleuronectes flesus, Anguilla anguilla). Comparative Biochemistry and Physiology C, Comparative Pharmacology and Toxicology, 2000, 125, 203-214.	0.5	12

#	Article	IF	CITATIONS
37	Plasma levels of neuroexcitatory amino acids in patients with migraine or tension headache. Journal of the Neurological Sciences, 1998, 156, 102-106.	0.6	86
38	Plasma cysteine and sulphate levels in patients with motor neurone, Parkinson's and Alzheimer's disease. Neuroscience Letters, 1990, 110, 216-220.	2.1	412
39	Monoamine oxidase substrates in Parkinson's disease. Biochemical Pharmacology, 1990, 40, 2562-2564.	4.4	15